Question special
Resident

I noticed that patients treated with dapagliflozin had a statistically significant increase in their hematocrit. In a recent editorial in JACC: Heart Failure, Vaduganathan et al. discussed that in the Cardio-link 6 Trial empagliflozin increased erythropoietin and suggest that SGLT-2 inhibitors may have other cardiometabolic effects that are beneficial beyond diuretic effect.

What do you think of this hypothesis?